search

All clinical trials

Results 9651-9660 of 470744

The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural...

Sudden DeafnessSudden Sensorineural Hearing Loss

Migraine and sudden sensorineural hearing loss(SSNHL) are two related disorders. A systemic steroid is usually used to treat SSNHL but the role of migraine prophylaxis medication remained unknown. Mehdi Abouzari et al. found a better improvement when combining topiramate and nortriptyline with steroids in a retrospective study. However, a prospective study with randomization is needed to elucidate the efficacy of these agents. This is a clinical study using medication approved and currently prescribed in the clinic. The included patients were those who came to the clinic and were diagnosed with SSNHL within 14 days of onset. Those patients were asked whether they agreed to participate in this clinical trial. Patients who were diagnosed with SSNHL but were later found to be other diseases such as Meniere's disease and cerebellopontine angle will be excluded from this study. The involved patients were randomized divided into two groups. Both groups received systemic steroids with/without intratympanic steroids. The experimental group receives additional oral topiramate for 6 weeks. Follow-up time is at least 3 months. This study is multi-center. Location of the study is performed at Chang gung memorial hospital Linkou branch, Taipei branch, Taoyuan branch, and New Taipei Municipal Tucheng Hospital.

Recruiting13 enrollment criteria

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine...

Relapsed/Refractory Peripheral T-cell Lymphoma

The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.

Recruiting50 enrollment criteria

Effectiveness of a 12-week Movement Intervention on Heart Rate Variability and Self-compassion Among...

Pregnancy Related

This is a mixed-methods randomized controlled trial assessing the effects of an online and in person 12-week movement intervention compared to an education only control group on heart rate variability, self-compassion, psychological well-being, fatigue, exercise self-efficacy, physical activity identity, and body image in postpartum women.

Recruiting4 enrollment criteria

Efficacy of Bupivacain Local Infiltration for the Management of Pain During Cesarean Section

PainPostoperative

This study aims to evaluate the effect of local administration of bupivacain in the cesarean section incision for postoperative pain control, using the visual analogue pain scale (VAS) and assessing the need for rescue analgesia after surgery.

Recruiting13 enrollment criteria

AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

Acute Myeloid Leukemia (AML) in Remission

This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.

Recruiting19 enrollment criteria

Fedratinib in Combination With Nivolumab

Primary MyelofibrosisSecondary Myelofibrosis

A multicenter, open-label, single arm, phase II study investigating the clinical efficacy of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment

Recruiting40 enrollment criteria

Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or...

Prostatic NeoplasmsCastration-Resistant

Hormone tablets, abiraterone (Zytiga®) and enzalutamide (Xtandi®) are approved to treat advanced prostate cancer. However, even if these drugs are helpful, their effectiveness usually diminishes over time. Small pilot studies have indicated that using hormone tablets sparingly, for just long enough to control the cancer, followed by a break in treatment and restarting them later, seems to improve how long hormone tablets can control the cancer. This study aims to find out if this pause/restart strategy is better than taking hormone tablets every day continuously. The study will include 168 people with metastatic castrate resistant prostate cancer in the Netherlands and Australia. Patients will be randomly 1:1 assigned between the control group and the experimental group. In the control group, patients will take the treatment with AA/ENZ every day until the prostate cancer doesn't respond anymore to the treatment. In the experimental group, patients will start with daily AA/ENZ until the PSA has declined for >50%. The treatment will then be paused and monthly PSA measurements will be performed. The treatment will be re-initiated when the PSA has increased to the level of before starting treatment. The treatment will be continued daily until the PSA has again dropped for >50%. This pause/restart cycle will be repeated until the prostate cancer doesn't respond anymore to the treatment.

Recruiting28 enrollment criteria

Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid...

Gastric AdenocarcinomaPancreatic Cancer1 more

An Open-Label, Single-Arm, Dose-Exploration Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of CT048 in Subjects with Advanced Solid Tumors

Recruiting28 enrollment criteria

A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors or Lymphoma

Advanced/Metastatic Solid Tumors or Lymphoma

This phase I, first-in-human, open-label clinical study will evaluate the safety, tolerability, kinetics and preliminary anti-tumor efficacy of intravenous infusion of HLX53 in patients with advanced or metastatic solid tumors or lymphoma for whom there is no standard therapy or no standard therapy available. HLX53 is an Fc fusion protein against TIGIT.

Recruiting26 enrollment criteria

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and...

Breast CancerSolid Tumor

In this study, the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase II dose (RP2D), the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 will be investigated in patients with unresectable locally advanced or metastatic breast cancer and other solid tumors.

Recruiting32 enrollment criteria
1...965966967...47075